Are patients in haemodialysis good candidates for immunotherapy treatment?

Fernandez-Diaz, Amaya B; Cunquero-Tomás, Alberto Jacobo; García-Medina, Adrian; Ferrer-Guillén, Blanca; Berrocal, Alfonoso

doi:10.1097/cmr.0000000000000616

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…На настоящий момент однозначно сложно делать выводы о прогнозе для пациентов с терминальной стадией ХБП на фоне иммунотерапии злокачественного новообразования. Необходимо проводить дальнейшие исследования в данной группе для получения более репрезентативных выборок и оценки прогноза в зависимости от гистологического типа опухоли [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37].…”

Section: иммунотерапия и хроническая болезнь почекunclassified

Nephrotoxicity of combination drug therapy in metastatic renal cancer

Titov,

Shutov,

Alimov

et al. 2023

Onkourologiâ

View full text Add to dashboard Cite

The review covers reduced kidney function in the context of renal cell carcinoma. According to international studies, some patients already have chronic kidney disease at time of disease onset. Surgical treatment leads to a decrease in the total number of functioning nephrons. Drug therapy causes several adverse events including nephrotoxicity. The review discusses the problem of using combination regimens in patients with solitary kidney.

show abstract

Section: иммунотерапия и хроническая болезнь почекunclassified

Nephrotoxicity of combination drug therapy in metastatic renal cancer

Titov,

Shutov,

Alimov

et al. 2023

Onkourologiâ

View full text Add to dashboard Cite

show abstract

Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review

Kitchlu

Jhaveri

Sprangers

et al. 2021

Clinical Kidney Journal

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICI), immunomodulatory antibodies that are used to enhance the immune system, have substantially improved the prognosis of patients with advanced malignancy. As use of ICI therapy becomes increasingly widespread across different types of cancer, their use in patients receiving dialysis is likely to increase. In this review, we summarize the current literature on use of ICI in ESKD patients and provide aggregate data from reported cases and series. Based on available pharmacological information, ICIs require no dosing adjustment in ESKD patients. Analysis of the reported cases in the literature demonstrates similar incidence of immune-related adverse events in patients with ESKD receiving dialysis as compared to the general population (49%). Severe reactions graded as 3 and 4 have been seen in fifteen patients (16%). As such, it is important that these patients are monitored very closely for irAE, however the risk of these adverse events should not preclude patients on dialysis from receiving these therapies. Cancer remission (complete and partial) was seen in close to 30% of patients. Stable disease was seen in 28% and progression of disease in approximately 36% of patients. One-third of the patients died. Urothelial and renal cell cancer represented approximately half of all treated cancers, and accounted for approximately 50% of all deaths reported. Additional data in the dialysis population with use of ICI, and involvement in prospective studies, is needed to better assess outcomes, particularly within specific cancer types.

show abstract

Are patients in haemodialysis good candidates for immunotherapy treatment?

Cited by 2 publications

References 6 publications

Nephrotoxicity of combination drug therapy in metastatic renal cancer

Nephrotoxicity of combination drug therapy in metastatic renal cancer

Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review

Contact Info

Product

Resources

About